Sangamo Therapeutics Files 8-K
Ticker: SGMO · Form: 8-K · Filed: May 13, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Sangamo filed an 8-K, likely routine updates. No major news yet.
AI Summary
On May 12, 2025, Sangamo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Sangamo Therapeutics is providing updates or submitting required documentation to the SEC, which could relate to ongoing business operations or financial reporting.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events, indicating low immediate risk.
Key Numbers
- 000-30171 — Commission File Number (Identifies the company's SEC filing record.)
- 68-0359556 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- SANGAMO THERAPEUTICS, INC. (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 501 Canal Blvd. (address) — Principal executive offices
- Richmond (location) — City of principal executive offices
- California (location) — State of principal executive offices
- 94084 (zip_code) — Zip code of principal executive offices
- 510-970-6000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating routine updates or submissions to the SEC.
When was the earliest event reported in this filing?
The earliest event reported is May 12, 2025.
In which U.S. state is Sangamo Therapeutics, Inc. incorporated?
Sangamo Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Sangamo Therapeutics, Inc.?
The principal executive office is located at 501 Canal Blvd., Richmond, California 94084.
What is Sangamo Therapeutics, Inc.'s telephone number?
The company's telephone number is (510) 970-6000.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding SANGAMO THERAPEUTICS, INC (SGMO).